Healthcare
ChromaDex Corp(CDXC)
Live Price
Offline$3.50
+3.86% today
1Y Change
-73.90%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $390.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +100.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ChromaDex Corp (CDXC) is a Healthcare stock with a market cap of $390.00M and listed on NASDAQ. The stock last traded around $3.50 and down 73.9% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +100.0%, free cash flow +10.6% with operating margin 11.0% and ROIC 15.6%. Valuation is more restrained than many high-expectation growth names at P/E 21.9 and price/sales 3.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CDXC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
+11.0% vs +19.4% peer median
P/E
Below sector median
21.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 4, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +100.0%, with operating margin around 11.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 4, 2026 | โ | +3.2% | -1.0% | -8.5% |
2025 Oct 29, 2025 | โ | -2.2% | -5.4% | -5.2% |
2025 Aug 5, 2025 | โ | +2.6% | +12.0% | +5.6% |
Benchmark Edge
CDXC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CDXC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CDXC Max Drawdown
-76.61%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CDXC and SPY.
Company Overview
ChromaDex Corp
NASDAQ
Niagen Bioscience Inc. is a bioscience company headquartered in Los Angeles, California. The company specializes in advancing NAD+ science to support cellular health and healthy aging through its proprietary Niagen platform, a patented NAD+-boosting ingredient known as nicotinamide riboside (NR). Niagen powers leading brands such as Tru Niagen, an oral supplement for consumer use, and Niagen Plus, which includes pharmaceutical-grade intravenous and injectable formulations available at clinics across the U.S. Niagen Bioscience Inc. operates ISO-accredited laboratories and maintains a reference standards business providing natural products, phytochemicals, and botanical reference materials for quality assurance in food, supplements, and research. It also runs the ChromaDex External Research Program, supplying high-quality NAD+ precursors to academic and government researchers worldwide. The company discovers, develops, and commercializes proprietary ingredient technologies targeting dietary supplements, food, beverages, skin care, and pharmaceutical markets, emphasizing science-backed innovation, clinical research, and regulatory compliance.
- Leadership
- Mr. Robert N. Fried
- Employees
- 117
- Street Address
- 10900 Wilshire Blvd, Suite 600
- Mailing
- Los Angeles, CA, 90024
- Region
- Los Angeles, CA, United States
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 21.9
- EV/EBITDA
- 19.5
- Price/Sales
- 3.0
- Price/Book
- 5.0
Growth
- Revenue
- -100.0%
- EPS
- +100.0%
- Free Cash Flow
- +10.6%
Profitability
- Gross Margin
- 64.3%
- Operating Margin
- 11.0%
- Net Margin
- 13.4%
- ROE
- 26.1%
- ROIC
- 15.6%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 4.86
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.